The recent developments in understanding antitumor HSP vaccine-mediated immunity has a promising potential to improve adoptive T cell transfer therapy, using patient's own T cells in conjunction with or independently of HSP anticancer vaccines, to recognize and kill tumor cells. Here, HSP90B2P is linked to neoplasm.